Senior Director, In Vivo Pharmacology

Repertoire Immune Medicines•Cambridge, MA

8d•$204,000 - $292,000

About The Position

Repertoire Immune Medicines is a clinical-stage biotechnology company harnessing the power of the human immune system to develop transformative therapies for cancer and autoimmune disease. Using its proprietary DECODETM platform—which maps the immune synapse between T cell receptors (TCRs) and their antigen targets—Repertoire translates unique biological insights into potent and targeted off-the shelf immune medicines. The company integrates deep protein engineering expertise with artificial intelligence, powered by a proprietary DECODE database of over one billion TCR-antigen interactions, to accelerate discovery and optimize drug candidates. From its sites in Cambridge, Massachusetts and Zurich, Switzerland, Repertoire is advancing a pipeline of T cell-targeted immunotherapies with the potential to address a broad range of cancers and autoimmune disorders. The company’s lead oncology program, RPTR-1-201, a TCR bispecific, has initiated a Phase 1/2 clinical trial across multiple solid tumor indications. Repertoire plans to advance additional TCR bispecific therapies into clinical trials over the next 12-18 months. In autoimmune disease, Repertoire is partnering with leading pharmaceutical companies to develop mRNA tolerizing therapies designed to selectively expand regulatory T cells and reset the immune system. Repertoire was founded in 2019 by Flagship Pioneering and is supported by a strong investor base. The DECODE platform has been validated through four strategic partnerships with leading pharmaceutical companies—Bristol Myers Squibb, Genentech, Eli Lilly, and Pfizer—representing over $4.5 billion in disclosed total deal value and $185 million in upfront payments received to date. Overview: Repertoire Immune Medicines is seeking a seasoned, immunology-focused pharmacology leader to shape and advance a portfolio of T cell–targeted therapies in oncology and autoimmune disease. Reporting to the SVP of Integrated Therapeutic Engineering and Development, this individual will play a leading role in development-stage research strategy and execution, driving programs from discovery through IND-enabling studies. This role requires deep scientific expertise and decisive leadership to define mechanism of action, establish PK/PD and efficacy relationships, and translate novel modalities—including both T cell engager and mRNA/LNP platforms—into clinically actionable programs. The successful candidate will ensure seamless integration across discovery, platform, and development functions. As a key member of the research team, this individual will influence portfolio direction and execution, accelerating the delivery of differentiated T cell–based therapies to patients.

Requirements

Ph.D. or equivalent in biology, pharmacology, or related discipline.
12+ years of experience in the biopharma industry, including at least 5 years leading cross-functional pharmacology and R&D teams within a biotechnology setting.
Deep expertise in preclinical development of immune-modulating therapies, with a demonstrated track record of advancing programs from discovery through IND and into clinical development.
Deep immune-oncology expertise and experience in developing in-vivo models and advancing immuno-oncology programs to preclinical in vivo proof of concept.
Ability to integrate multidisciplinary data and perspectives to drive clear, data-informed decision-making.
Excellent verbal and written communication skills, with the ability to convey complex scientific concepts to diverse audiences.
Demonstrated ability to influence, align, and lead stakeholders at all levels around a strategic scientific vision. Strong track record of scientific leadership and team development within a drug discovery and development environment.

Nice To Haves

Understanding of autoimmune disease biology is strongly preferred.
Experience translating preclinical data into human dose projections including PK/PD relationships informed by QSP modeling is highly desirable
Experience with LNP-delivered therapeutics is a plus but not required.

Responsibilities

Lead in vivo pharmacology strategy and execution across oncology and autoimmune disease programs, with a focus on T cell engager modalities, driving translational insight and shaping IND-enabling paths.
Set scientific vision and operational strategy for MOA and IND-enabling pharmacology, ensuring robust data packages that support pipeline progression and portfolio expansion.
Provide end-to-end operational leadership for in vivo studies, including experimental design, CRO selection and oversight, data interpretation, reporting, and timeline delivery.
Lead a multidisciplinary team (~7 scientists) spanning in vivo pharmacology, RNA biology, and LNP formulation, fostering a high-performance, collaborative environment.
Partner cross-functionally with applied immunology, translational and platform teams to translate discovery insights into in vivo proof-of-concept.
Identify and leverage external partners (CROs, consultants) to compliment internal FTES, to maximize efficiency and delivery.